Fig. 3

Proportion of patients With ≥ 30%, ≥ 50%, and ≥ 75% reduction in number of monthly headache days of any severity. Green represents patients treated with 140-mg erenumab, light: ≥ 30%, medium: ≥ 50%, and dark: ≥ 75%. Orange represents patients treated with 70-mg erenumab, light: ≥ 30%, medium: ≥ 50%, and dark: ≥ 75%. Participants with data available for analysis; Weeks 9–12, n = 273; Weeks 13–24, n = 162; Weeks 25–36; 140-mg, n = 121; 70-mg, n = 27; Weeks 41–52; 140-mg, n = 95; 70-mg, n = 24